Xtandi- The Real Potential and the Astellas Part!

May 4, 2013 - PRLog -- "Xtandi- The Real Potential and the Astellas Part!

Please visit the link https://www.reportscorner.com/reports/15823/Xtandi--The-Real-Potential-and-the-Astellas-Part!/

Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to treat prostate cancer as an ideal antiandrogen therapy (includes positive expectation from interim analysis of PREVAIL expected at ESMO-13/ early 4Q 2013 study in pre-chemo setting) has recently resulted in a rally in Astellas’ price.  Although, the clinical profile of Xtandi (steroid free regimen, better safety and efficacy than Zytiga) carries potential to compete with Casodex/Zytiga generics post 2016, we think that emerging new candidates (ARN-509, ODM-021, TAK-700) create some threat for Xtandi and the agreement between Astellas and Medivation is not lucrative enough for Astellas.  Xtandi’s major sales will come from metastatic pre-chemo setting due to………
Pre-chemo vs. Post chemo Market size: Metastatic Pre chemo market 3 times bigger than post chemo; Zytiga 1Q 2013 sales reveal this basis……"